7 alpha-hydroxy-4-cholesten-3-one has been researched along with Dyslipidemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, Y; Haba, M; Shimada, M; Shinozawa, E; Tozawa, R; Yamakawa, H | 1 |
| Camilleri, M; Graffner, H; Holst, JJ; Rikner, L; Rudling, M | 1 |
1 trial(s) available for 7 alpha-hydroxy-4-cholesten-3-one and Dyslipidemia
| Article | Year |
|---|---|
Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bile Acids and Salts; Cholestenones; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Constipation; Dipeptides; Dyslipidemias; Female; Glucagon-Like Peptide 1; Humans; Lipids; Male; Middle Aged; Thiazepines; Triglycerides; Young Adult | 2015 |
1 other study(ies) available for 7 alpha-hydroxy-4-cholesten-3-one and Dyslipidemia
| Article | Year |
|---|---|
Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents.
Topics: Animals; Apolipoprotein A-I; Benzoates; Bile Acids and Salts; Cell Line, Tumor; Cholestenones; Cholesterol; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Feces; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Mesocricetus; Piperidines; Receptors, Cytoplasmic and Nuclear; Triglycerides | 2018 |